HHS opens the door to compounded wellness peptides — with strings attached

HHS Secretary Robert F. Kennedy Jr. has issued an "enforcement discretion policy" that clears the way for pharmacies, physicians, and federal facilities to compound six wellness peptides — BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500 — without facing federal enforcement action. The move stops short of formally approving the compounds but signals a significant shift in how the federal government treats these increasingly popular substances.

The decision follows a July FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, where panelists voted to recommend adding the six peptides to the 503A Bulk Drug Substances list. That vote was advisory, not binding, and the peptides remain unapproved. Kennedy cited strong patient demand and a lack of approved alternatives as key justifications.

Key Takeaways:

• Compounders must source bulk drug substances from FDA-registered facilities and meet strict quality standards
• Adverse events and quality issues must be reported, whether or not the drug is deemed directly responsible
• The policy may be revisited if new safety signals or quality problems emerge
• Critics, including Public Citizen, argue the move bypasses necessary FDA oversight for compounds that remain unproven and unapproved

Why it matters: Millions of patients are already sourcing these peptides through unregulated channels. Proponents argue this policy creates a safer, more accountable supply chain — but without formal FDA approval, questions about safety, efficacy, and regulatory consistency remain wide open.